Phase 4 Haemophilia Trial, Recruiting NCT04647227 Sponsor: American Thrombosis and Hemostasis Network Condition: Haemophilia
Back to Haemophilia

Phase 4 Haemophilia Trial, Recruiting

NCT04647227
Recruiting Phase 4

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • People who have been diagnosed with hemophilia A or B with inhibitors
  • People who are 12 years of age or older
  • People who are able to understand and follow the study requirements, or who have a parent or legal guardian who is able to do so on their behalf
  • People who have read, understood, and signed a consent form agreeing to take part
  • People who are able to provide past medical records showing previous inhibitor level results
  • People who are willing and able to use a mobile app or paper diary to record bleeding events and medication use

Who may not be able to join:

  • People who have an additional blood clotting disorder on top of their hemophilia A or B
  • People who have a known or suspected intolerance or allergic reaction to SEVENFACT® or any of its ingredients
  • People who have a known allergy or sensitivity to rabbits or rabbit proteins
  • People who are receiving a preventive bleeding treatment (drug or biological therapy) that the FDA has not approved for that specific use
  • People who have had an investigational medical device implanted in the 6 months before the study
  • People who have taken an investigational (unapproved) drug within 30 days of the study's starting visit
  • People who have a planned elective surgery scheduled during the time they would be taking part in the study
  • People who have a life-threatening illness, or any other disease or condition that the study doctor believes could put them at risk or interfere with the study (for example, a history of not responding to bypassing treatments, or a history of blood clot disorders)

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 23 July 2026
Phase 4 trials study a drug that has already been approved, monitoring long-term safety and effectiveness in real-world use.

Contact this trial

Principal Investigator: Tammuella Chrisentery-Singleton, MD, American Thrombosis and Hemostasis Network

Phone: (800)-360-2846

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Phase 4
Sponsor
American Thrombosis and Hemostasis Network
Registry
ClinicalTrials.gov
Start date
28 June 2021
Est. completion
30 September 2026

Where this trial is recruiting

🇺🇸 United States

Primary endpoints

Number of participants and percentage of Safety Events (AEs)

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 23 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov